Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Statement of Comprehensive Income

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Bristol-Myers Squibb Co., consolidated statement of comprehensive income

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net earnings (loss)
Derivatives qualifying as cash flow hedges
Pension and postretirement benefits
Marketable debt securities
Foreign currency translation
Other comprehensive income (loss)
Comprehensive income (loss)
Comprehensive income attributable to noncontrolling interest
Comprehensive income (loss) attributable to BMS

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Comprehensive income item Description The company
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Comprehensive income (loss) attributable to BMS Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners. Bristol-Myers Squibb Co. comprehensive income (loss) attributable to BMS decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.